For instance, if AID has been identified as a potential cause for iron deficiency in a cancer patient, a favourable therapy regimen must include newer or combination therapeutics maintaining lower anaemia incidence and risk rates. The gene discussed is AICDA; the disease is Iron deficiency anemia.